title: [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
abstract: OBJECTIVE
  To determine the incidence and clinical significance of chromosome 13q14 deletion in multiple myeloma (MM).
  
  
  METHODS
  Bone marrow samples were collected from 132 newly diagnosed MM patients referred to our hospital. Interphase fluorescence in situ hybridization (i-FISH) combined with magnetic activated cell sorting (MACS) were performed on chromosome 13q14 (RB-1).
  
  
  RESULTS
  (1) i-FISH was used to investigate CD138-enriched bone marrow MM cells and revealed a 13q14 deletion rate of 51.5% (68/132), while conventional cytogenetic (CC) analysis revealed 13q deletions/monosomy 13 (Δ13) only of 5.0%(6/120). (2) Univariate analysis showed that 13q14 deletion rate by i-FISH > 25%, bone marrow plasma cells > 50%, ISS stage and β(2)-MG ≥ 5.5 mg/L were associated with shorter overall survival (OS). Multivariate analysis revealed that 13q14 deletion rate by i-FISH > 25% was an independent unfavorable factor (P = 0.042). (3) Patients treated with bortezomib had a much better response than those treated with traditional chemotherapy (P = 0.001). There was no significant difference in OS between patients received bortezomib with and without 13q14 deletion (P > 0.05), indicating that bortezomib could reverse the poor prognosis of 13q14 deletion.
  
  
  CONCLUSIONS
  (1) i-FISH followed CD138 cell sorting appears to be a highly sensitive method for detecting 13q14 deletion. (2) 13q14 deletion rate by i-FISH > 25% is an independent unfavorable factor. (3) Bortezomib could reverse the poor prognosis of 13q14 deletion.
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Gang
authors.initials: G
authors.lastname: An
authors.forename: Cheng-wen
authors.initials: CW
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.forename: Shu-hui
authors.initials: SH
authors.lastname: Deng
authors.forename: Xu-ping
authors.initials: XP
authors.lastname: Liu
authors.forename: Jun-yuan
authors.initials: JY
authors.lastname: Qi
authors.forename: Ya-fei
authors.initials: YF
authors.lastname: Wang
authors.forename: De-hui
authors.initials: DH
authors.lastname: Zou
authors.forename: Yao-zhong
authors.initials: YZ
authors.lastname: Zhao
authors.forename: Lu-gui
authors.initials: LG
authors.lastname: Qiu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002872:Chromosome Deletion; D025063:Chromosome Disorders; D002882:Chromosomes, Human, Pair 13; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib